• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Metabolic consideration on PFK isozymes with reference to the first and the second phase of insulin secretory response from the pancreatic beta cells.

Research Project

Project/Area Number 10671068
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Metabolomics
Research InstitutionOsaka University

Principal Investigator

NAKAJIMA Hiromu  Osaka University Gradutae School of Medicine, Assistant Professor, 医学系研究科, 助手 (50252680)

Co-Investigator(Kenkyū-buntansha) YAMASAKI Tomoyuki  Osaka University Medical School, Assistant Professor, 医学部, 助手 (00303975)
KITAJIMA Koichi  Osaka University Graduate School of Medicine, Assistant Professor, 医学系研究科, 助手 (00314310)
HANAFUSA Toshiaki  Osaka University Graduate School of Medicine, Lecturer, 医学系研究科, 講師 (60164886)
HAMAGUCHI Tomoya  Osaka University Hospital, Medical Staff, 医学部・附属病院, 医員
Project Period (FY) 1998 – 1999
Project Status Completed (Fiscal Year 1999)
Budget Amount *help
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 1999: ¥1,400,000 (Direct Cost: ¥1,400,000)
Fiscal Year 1998: ¥1,700,000 (Direct Cost: ¥1,700,000)
Keywordsphosphofructokinase / pancreatic B cell / insulin secretion / glucose metabolism / regulatory system / glucose responsiveness / isozyme / gene expression / グルコースセンサー / アロステリック調節 / アンチセンス / ノックアウト / 糖尿病
Research Abstract

In the pancreatic beta cells, the mode of insulin secretion in response to glucose is known as biphasic. In the first phase of insulin secretion, glucokinase (GK) acts as a glucose sensor, regulating the glucose flux and ATP synthesis rate. But if we try to explain the biphasic profile of insulin secretion through the metabolic consideration, only the nonallosteric GK component is not sufficient for a biphasic mode of reaction.
There are three distinct isozymes in phosphofructokinase (PFK), the other key regulatory enzyme of glycolysis in the liver, as well as in the beta cell. We have shown that expression of all three isozymes of L (liver form), M (muscle form) and P (platelet, brain or fibroblast form) is seen in the pancreatic tissue. Among these, the major isozymes in the beta cells are L and M forms. Both isozymes of PFK are well-known typical allosteric enzymes. To note, the attitue of allosteric inhibition by ATP and citrate is more steep in PFK-M than in PFK-L. Activation by AD … More P/AMP is stronger in PFK-M. The first stage of glucose entry to beta cells would be characterized by low ATP/ADP ratio and low citrate levels. Then PFK-M dominantly works the intermediate glycolytic step. When the steady state glucose uptake and phosphorylation are established and intracellular contents of ATP and citrate are increased, allosteric inhibition affects more on PFK-M and glycolysis will go on mainly by PFK-L. The latter phenomenon may responsible for characterizing the second phase of insulin secretory response in view from the metabolic consideration.
To evaluate and examine this hypothesis, we are trying to knockout the specific PFK isozyme in the beta cells.
We have established in this research process, the precise analytical methods applicable to living cells for the determination of intracellular calcium ion, proton and ATP concentrations by using the real-time cell-imaging analyzer, confocal laser microscopy, and luciferase overexpression system, respectively.
We are now establishing the cellular knockout of PFK isozymes in MIN6 cells by the stable transformation of antisense RNA expression system. Transient overexpression of antisense vector is also prepared by the adenoviral system. The latter is aimed to evaluate the hypothesis using the isolated islets and pancreas organ perfusion.
During this research period, establishment of the specific knockout system and the cytoanalytical system have been prepared. These will be used in the following study periods and the forthcoming results will give further rationale for establishing isozyme specific knockout mice to determine the whole body effect of beta cell PFK isozymes. Less

Report

(3 results)
  • 1999 Annual Research Report   Final Research Report Summary
  • 1998 Annual Research Report
  • Research Products

    (24 results)

All Other

All Publications (24 results)

  • [Publications] Iizuka, K., et al.: "Stable overexpression of the glucose-6-phosphatase catalytic subunit attenuates glucose sensitivity of insulin secretion from a mouse pancreatic beta cell line"J. Endocrinol.. 164・3. 307-314 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Iwashi, H., et al.: "Emerging therapeutic strategies in autoimmune diabetes : aetiology, prediction, prevention and cure"Emerging Therapeutic Targets. 3・1. 177-193 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Oue, T., et al.: "Risk factors for the progression of microalbuminuria in Japanese type 2 diabetic patients : a 10-year follow-up study"Diabetes Res Clin Practice. 46・10. 47-52 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Moriwaki, M., et al.: "Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with resent-onset Type I diabetes mellitus"Diabetelogia. 42・11. 1332-1340 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Yoshiuchi, H., et al.: "Mutation/polymorphisms of pancreatic beta-cell destruction in autoimmune diabetes : potential targets for preventive therapy"J. Clin. Endocrinol. Metab.. 83・3. 1016-1019 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Iwashi, H., et al.: Cytokine, Cellular & Molecular Therapy. 4・1. 45-51 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] K.Iizuka, H. Nakajima, A. Ono, K. Okita, J. Miyazaki, J. Miyagawa, M. Namba, T. Hanafusa, Y. Matsuzawa: "Stable overexpression of the glucose-6-phosphatase catalytic subunit attenuates glucose sensitivity of insulin secretion from a mouse pancreatic beta cell line."J. Endocrinol. 164 (3). 307-314 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] H.Iwahashi, T. Hanafusa, A. Imagawa, K. Tomita, M. Moriwaki, K. Yamamoto, M. Waguri, K. Yamagata, N. Itoh, I. Yoshiuchi, T. Nanmo, H. Nakajima, J. Miyagawa, M. Namba, Y. Matsuzawa: "Emerging therapeutic strategies in autoimmune diabetes : aetiology, prediction, prevention and cure."Emerging Therapeutic Targets. 3 (1). 177-193 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] T. Oue, M. Namba, H. Nakajima, A. Ono, Y. Horikawa, K. Yamamoto, T. Hamaguchi, H. Fujino-Kurihara, T. Yamasaki, K. Tomita, J. Miyagawa, T. Hanafusa, Y. Matsuzawa: "Risk factors for the progression of microalbuminuria in Japanese type 2 diabetic patients : a 10-year follow-up study."Diabetes Res Clin Practice. 46 (10). 47-52 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] M. Moriwaki, N. Itoh, J. Miyagawa, K. Yamamoto, A. Imagawa, K. Yamagata, H. Iwahashi, H. Nakajima, M. Namba, S. Nagata, T. Hanafusa, Y. Matsuzawa: "Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with resent-onset Type I diabetes mellitus."Diabetelogia. 42 (11). 1332-1340 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] I. Yoshiuchi, R. Shingu, H. Nakajima, T. Hamaguchi, Y. Horikawa, T. Yamasaki, T. Oue, A. Ono, J. Miyagawa, M. Namba, T. Hanafusa, Y. Matsuzawa: "Mutation/polymorphism scanning of Glucose-6-Phosphatase Gene Promoter in Non Insulin Dependent Diabetes Mellitus Patients."J. Clin. Endocrinol. Metab.. 83 (3). 1016-1019 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] H. Iwahashi, N. Itoh, K. Yamagata, A. Imagawa, H. Nakajima, K. Tomita, M. Moriwaki, M. Waguri, K. Yamamoto, J. Miyagawa, M. Namba, T. Hanafusa, Y. Matsuzawa: "Molecular mechanisms of pancreatic beta-cell destruction in autoimmune diabetes : potential targets for preventive therapy."Cytokine, Cellular & Molecular Therapy. 4 (1). 45-51 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1999 Final Research Report Summary
  • [Publications] Iizuka K.et al.: "Stable overexpression of the glucose-6-phosphatase catalytic subunit attenuates glucose sensitivity of insulin secretion from a mouse pancreatic beta cell line"J. Endocrinol.. 164・3. 307-314 (2000)

    • Related Report
      1999 Annual Research Report
  • [Publications] Iwahashi H.et al.: "Emerging therapeutic strategies in autoimmune diabetes: aetiology, prediction, prevention and cure"Emerging Therapeutic Targets. 3・1. 177-193 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Oue T.et al.: "Risk factors for the progression of microalbuminuria in Japanese type 2 diabetic patients: a 10-year follow-up study"Diabetes Res Clin Practice. 46・10. 47-52 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Moriwaki M.et al.: "Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with resent-onset Type I diabetes mellitus"Diabetelogia. 42・11. 1332-1340 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Yoshiuchi I.et al.: "Mutation/polymorphism scanning of Glucose-6-Phosphatase Gene Promoter in Non Insulin Dependent Diabetes Mellitus Patients"J. Clin. Endocrinol. Metab.. 83・3. 1016-1019 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] Iwahashi H.et al.: "Molecular mechanisms of pancreatic beta-cell destruction in autoimmune diabetes: potential targets for preventive therapy"Cytokin, Cellular & Molecular Therapy. 4・1. 45-51 (1998)

    • Related Report
      1999 Annual Research Report
  • [Publications] Yoshiuchi I,et al.: "Three new mutations in the hepatocyte nuclear factor-1α gene in Japanese subjects with diabetes mellitus:Clinical features and functional characterization." Diabetologia. in press.

    • Related Report
      1998 Annual Research Report
  • [Publications] Terauchi Y,et al.: "Increased insulin sensitivity and hypoglycemia in mice lacking p85α regulatory subunit of phosphoinositide 3-kinase." Nat Genet. 21(2). 230-235 (1999)

    • Related Report
      1998 Annual Research Report
  • [Publications] Yamagata K,et al.: "Mutation P291 fsinsC in the transcription factor hepatocyte nuclear factor-1α is dominant negative." Diabetes. 47(8). 1231-1235 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Kuwajima M,et al.: "Characteristics of cardiac hypertrophy in the juvenile visceral steatosis mouse with systemic carnitine deficiency." J Mol Cell Cardiol. 30(4). 773-781 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Iwahashi H,et al.: "Molecular mechanisms of pancreatic beta-cell destruction in autoimmune diabetes:potential targets for preventive therapy." Cytokines Cell Mol Ther. 4(1). 45-51 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Yoshiuchi I,et al.: "Mutation/polymorphism scanning of glucose-6 phosphatase gene promoter in noninsulin-dependent diabetes mellitus patients." J Clin Endocrinol Metab. 83(3). 1016-1019 (1998)

    • Related Report
      1998 Annual Research Report

URL: 

Published: 1998-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi